Your topics. New publications.

A compact browser notification when there’s something new. At most once a day — no account needed.

What interests you?

Optional and switchable off here at any time. We save your selected topics and device subscription; no email address is required. Privacy

Search the harborEN/DEAccount
Hallmarks of aging
Research brief

Proposed RNA-damage framework and tDamAge clock in mice and human blood

The abstract presents a proposed computational framework that scores four kinds of aberrant RNA transcripts from standard RNA-sequencing data, and a machine-learning tDamAge clock trained on mouse tissues or human peripheral blood that predicted age and shifted under pro-aging and anti-aging conditions. [1]

Automatic summary · not editorially reviewed

The key findings

  1. The proposed framework quantifies damage from standard RNA-sequencing data across four classes of aberrant transcript structures. [1]

  2. The tDamAge clock used machine-learning models trained across mouse tissues or human peripheral blood and could predict age. [1]

  3. The authors report elevated damage age acceleration in Alzheimer's disease and rejuvenation-like reductions during embryonic development. [1]

The source at a glance

Study type / format
Abstract of a computational methods and biomarker study
Population / context
Mouse tissues and human peripheral blood samples analyzed with RNA-sequencing data, including progeroid models, intervention conditions, Alzheimer's disease and embryonic development.
Summary based on
Study abstract
Publication status
Preprint · peer-review status not confirmed
Original publication
June 29, 2026

Proposed RNA-damage score from sequencing data

The authors describe a computational framework that quantifies damage from standard RNA-sequencing data. It captures four classes of aberrant transcript structures: premature termination upon intron retention, domain-disrupting splice variants, repeat elements and gene fusion events. Each class is said to reflect a distinct form of RNA integrity loss. This is a proposed method, not a validated product.

Supporting source [1]

tDamAge clock trained on mouse tissues or human blood

To combine the measurements into one biomarker, the authors built a transcriptomic damage-based aging clock, tDamAge, using machine-learning models trained across mouse tissues or human peripheral blood. It could predict age and detect transcriptomic shifts under both pro-aging and anti-aging conditions. Progeroid models showed accelerated tDamAge, while caloric restriction, rapamycin and methionine restriction lowered tDamAge.

Supporting source [1]

Cross-dataset patterns, Alzheimer findings and embryonic reversal

Cross-dataset analysis indicated that diverse anti-aging interventions converge on shared transcriptomic signatures, particularly RNA processing and chromatin organization pathways, and that these age-associated patterns could be reversed by interventions. The authors also report elevated damage age acceleration in Alzheimer's disease and rejuvenation-like reductions during embryonic development. They conclude that tDamAge could detect age progression, acceleration, deceleration and reversal.

Supporting source [1]

How to interpret this

This is an abstract; the full text was not reviewed. The framework and tDamAge clock are proposed methods, and the reported associations, including intervention effects and disease patterns, are not established causes or human lifespan benefits.

Based on the study abstract; the full paper, tables and supplementary data were not reviewed.

Source & supporting passages

[1]
Causally measuring aging and rejuvenation through transcriptomic damage

Zhang S, Iqbal S, Tyshkovskiy A, Gladyshev VN. · europepmc.org · June 29, 2026

Read the quoted passagesIn the language of the original source
  1. Finding 1 ↑

    quantify damage from standard RNA-sequencing data
  2. Finding 2 ↑

    trained across mouse tissues or human peripheral
  3. Finding 3 ↑

    rejuvenation-like reductions during embryonic development

AI-assisted summary with linked source passages. No independent editorial or clinical review.

Our editorial method

Discussion

Community discussions

0 topics

Member contributions. Share sources, disclose commercial interests, and avoid personal medical or dosing advice.

Loading…